Company research
AGENUS INC
CIK 1098972Updated Nov 17, 2026
AGEN price & chart
Loading TradingView…
NASDAQ:AGEN on TradingView ↗About the company
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
In the news
Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies News provided by Zydus Lifesciences Jun 03, 2025, 08:00 ET Share this article Share to X Share this article Share to X The acquisition will establis ↗
Seeking Alpha
Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial - Slideshow ↗
Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial Transcript ↗
At a glance: stocks gapping up premarket ↗
SEC disclosures
AGENUS INC files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-3 filing
S-8 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02
Show 5 more recent filings
424B3 filing
EFFECT filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 233,891,000Source | 238,482,000Source | 172,692,000Source | 185,221,000Source | 292,415,000Source | 186,456,000Source | 200,201,000Source | 256,559,000Source | 226,798,000Source | 226,271,000Source | 313,913,000Source | 413,556,000Source |
| Property, Plant and Equipment, NetUSD | 15,987,000Source | 124,472,000Source | 14,322,000Source | 112,722,000Source | 127,569,000Source | 14,947,000Source | 117,030,000Source | 130,330,000Source | 15,470,000Source | 120,087,000Source | 133,421,000Source | 133,017,000Source |
| GoodwillUSD | 24,092,000Source | 24,694,000Source | 24,092,000Source | 24,092,000Source | 24,748,000Source | 24,092,000Source | 24,092,000Source | 24,698,000Source | 24,092,000Source | 24,092,000Source | 24,723,000Source | 25,467,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,122,000Source | 3,955,000Source | 2,880,000Source | 3,206,000Source | 4,136,000Source | 2,959,000Source | 3,291,000Source | 4,230,000Source | 3,037,000Source | 3,376,000Source | 4,411,000Source | 6,228,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,458,000Source | 44,784,000Source | 18,738,000Source | 9,534,000Source | 93,723,000Source | 34,996,000Source | 18,488,000Source | 52,856,000Source | 2,998,000Source | 40,437,000Source | 76,110,000Source | 178,674,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 538,000Source | 207,000Source | 14,725,000Source | 709,000Source | 719,000Source | 6,562,000Source | 354,000Source | 476,000Source | 1,831,000Source | 407,000Source | 25,836,000Source | 2,741,000Source |
| Assets, CurrentUSD | 133,950,000Source | 50,154,000Source | 78,810,000Source | 13,340,000Source | 100,004,000Source | 95,284,000Source | 23,138,000Source | 60,352,000Source | 133,436,000Source | 45,574,000Source | 112,416,000Source | 213,122,000Source |
| Operating Lease, Right-of-Use AssetUSD | 8,027,000Source | 28,612,000Source | 7,205,000Source | 26,421,000Source | 28,964,000Source | 7,458,000Source | 27,046,000Source | 29,340,000Source | 7,744,000Source | 27,308,000Source | 29,606,000Source | 31,269,000Source |
| Other Assets, NoncurrentUSD | 3,188,000Source | 6,595,000Source | 3,856,000Source | 5,440,000Source | 6,994,000Source | 3,013,000Source | 5,604,000Source | 7,609,000Source | 3,307,000Source | 5,834,000Source | 9,336,000Source | 4,453,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 329,000Source | 217,000Source | 427,000Source | 300,000Source | 211,000Source | 385,000Source | 266,000Source | 210,000Source | 353,000Source | 236,000Source | 3,944,000Source | 3,056,000Source |
| Additional Paid in CapitalUSD | 1,899,281,000Source | 1,845,815,000Source | 1,945,037,000Source | 1,882,704,000Source | 1,830,114,000Source | 1,922,370,000Source | 1,867,500,000Source | 1,816,985,000Source | 1,911,740,000Source | 1,857,662,000Source | 1,792,348,000Source | 1,644,658,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,172,187,000Source | -2,137,021,000Source | -2,144,089,000Source | -2,236,101,000Source | -2,070,635,000Source | -2,143,539,000Source | -2,208,146,000Source | -2,017,554,000Source | -2,182,765,000Source | -2,182,880,000Source | -1,955,668,000Source | -1,709,907,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,560,000Source | -1,347,000Source | -450,000Source | -1,504,000Source | -1,001,000Source | -437,000Source | -1,468,000Source | -1,071,000Source | -439,000Source | -1,398,000Source | -955,000Source | 915,000Source |
| Stockholders' Equity Attributable to ParentUSD | -274,137,000Source | -292,336,000Source | -199,075,000Source | -354,601,000Source | -241,311,000Source | -221,221,000Source | -341,848,000Source | -201,430,000Source | -271,111,000Source | -326,380,000Source | -160,331,000Source | -61,278,000Source |
| Liabilities and EquityUSD | 233,891,000Source | 238,482,000Source | 172,692,000Source | 185,221,000Source | 292,415,000Source | 186,456,000Source | 200,201,000Source | 256,559,000Source | 226,798,000Source | 226,271,000Source | 313,913,000Source | 413,556,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 287,132,000Source | 270,644,000Source | 231,820,000Source | 234,563,000Source | 270,666,000Source | 249,237,000Source | 208,304,000Source | 256,002,000Source | 323,489,000Source | 221,401,000Source | 255,897,000Source | 188,952,000Source |
| Operating Lease, Liability, CurrentUSD | 1,113,000Source | 2,427,000Source | 1,102,000Source | 2,496,000Source | 2,296,000Source | 1,054,000Source | 2,525,000Source | 2,811,000Source | 1,034,000Source | 2,446,000Source | 2,587,000Source | 1,943,000Source |
| Accounts Payable, CurrentUSD | 85,289,000Source | 45,899,000Source | 58,984,000Source | 74,396,000Source | 50,843,000Source | 71,084,000Source | 64,240,000Source | 50,693,000Source | 82,987,000Source | 61,470,000Source | 61,446,000Source | 40,939,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,383,000Source | 55,164,000Source | 9,538,000Source | 53,394,000Source | 55,786,000Source | 9,827,000Source | 53,982,000Source | 61,756,000Source | 10,108,000Source | 54,551,000Source | 62,511,000Source | 63,326,000Source |
| Other Liabilities, NoncurrentUSD | 376,000Source | 777,000Source | 247,000Source | 752,000Source | 1,490,000Source | 247,000Source | 761,000Source | 2,732,000Source | 259,000Source | 738,000Source | 5,420,000Source | 13,826,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -6,731,000Source | 20,532,000Source | -6,775,000Source | 18,293,000Source | 20,472,000Source | -6,762,000Source | 19,450,000Source | 11,107,000Source | -6,750,000Source | 19,956,000Source | 11,949,000Source | 6,376,000Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | — | — | — | — | 500,000Source | — | — | 800,000Source | — |
| Accrued Liabilities, CurrentUSD | 31,752,000Source | 36,695,000Source | 27,515,000Source | 39,311,000Source | 41,208,000Source | 36,987,000Source | 36,444,000Source | 41,291,000Source | 34,223,000Source | 34,961,000Source | 45,283,000Source | 38,259,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 3,500,000Source | 44,800,000Source | — | 9,500,000Source | 93,700,000Source | — | 18,500,000Source | 52,900,000Source | — | 40,400,000Source | 76,100,000Source | 193,400,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 112,000Source | 112,000Source | 112,000Source | 911,000Source |
| Long-term Debt, Current MaturitiesUSD | 10,610,000Source | 13,401,000Source | 30,068,000Source | 10,721,000Source | 13,425,000Source | 30,193,000Source | 731,000Source | 13,575,000Source | 44,655,000Source | 2,698,000Source | 146,000Source | 575,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 23,599,000Source | 0Source | — | 23,151,000Source | 0Source | — | 32,846,000Source | 0Source | 0Source | 30,473,000Source | 12,768,000Source | 12,584,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 14,684,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 63,911,000Source | -67,214,000Source | -567,000Source | -30,012,000Source | 39,206,000Source | -26,370,000Source | -3,083,000Source | -232,271,000Source | -257,437,042Source | -230,656,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,098,000Source | 3,482,000Source | 13,770,000Source | 17,390,000Source | 22,869,000Source | 18,337,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 4,731,000Source | -108,000Source | 1,728,000Source | -25,344,000Source | 23,461,000Source | -122,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -11,880,000Source | 2,642,000Source | 23,500,000Source | 2,013,000Source | 21,366,000Source | 6,494,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -35,950,000Source | -25,618,000Source | -77,195,000Source | -158,315,000Source | -224,202,000Source | -175,373,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 68,952,000Source | 57,000Source | 1,194,000Source | 27,000Source | 3,400,000Source | -33,610,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 5,000Source | 6,000Source | 576,000Source | 9,954,000Source | 53,062,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -993,000Source | 3,594,000Source | 36,593,000Source | 122,840,000Source | 119,866,000Source | 95,830,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 8,413,000Source | 2,500,000Source | 2,500,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 31,998,000Source | -21,949,000Source | -39,361,000Source | -35,708,000Source | -101,564,000Source | -113,257,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 188,000Source | 387,000Source | 1,175,000Source | 2,278,000Source | 3,168,000Source | 1,143,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,808,000Source | 9,280,000Source | 3,260,000Source | 3,441,000Source | 866,000Source | 3,333,000Source | 11,896,000Source | 27,327,000Source | 22,351,000Source | 18,238,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 300,000Source | 500,000Source | 1,500,000Source | 2,200,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 3,500,000Source | 44,800,000Source | — | 9,500,000Source | — | 18,500,000Source | — | 40,400,000Source | 76,100,000Source | 193,400,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 9,700,000Source | 12,800,000Source | 11,900,000Source | 4,700,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -200,000Source | -29,000Source | -100,000Source | -400,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | 0Source | 0Source | 40,379,000Source | 0Source | -937,000Source | -1,153,000Source | 1,408,000Source | 16,196,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | 5,300,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 10,860,000Source | 17,275,000Source | 8,466,000Source | 15,518,000Source | 6,860,000Source | 15,718,000Source | 54,392,000Source | 71,878,000Source | 78,739,000Source | 81,007,000Source |
| GoodwillUSD | — | — | 24,092,000Source | 24,694,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,092,000Source | 24,723,000Source | 25,467,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 602,000Source | 0Source | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | 2,526,000Source | 0Source | -1,350,000Source | 0Source | -26,345,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 13,244,000Source | 36,748,000Source | 15,363,000Source | 13,343,000Source | 14,690,000Source | 12,983,000Source | 55,618,000Source | 120,421,000Source | — | — |
| Investment Income, InterestUSD | — | — | 74,000Source | 1,019,000Source | 121,000Source | 54,000Source | 21,000Source | 188,000Source | 345,000Source | 2,795,000Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -3,000Source | -828,000Source | -17,000Source | -2,057,000Source | -20,000Source | -1,104,000Source | -3,198,000Source | -5,059,000Source | -11,676,000Source | -10,582,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 63,860,000Source | -66,440,000Source | -604,000Source | -28,009,000Source | 39,172,000Source | -25,320,000Source | -101,000Source | -227,427,000Source | -245,974,000Source | -220,286,000Source |
| Nonoperating Income (Expense)USD | — | — | -19,298,000Source | 19,000Source | 856,000Source | -12,000Source | -208,000Source | -264,000Source | -2,220,000Source | 5,830,000Source | 37,000Source | 12,571,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 200,000Source | 900,000Source | — | 6,100,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 81,626,000Source | 19,000Source | 3,382,000Source | -12,000Source | 38,821,000Source | -264,000Source | 72,359,000Source | 5,830,000Source | — | — |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | -1,559,000Source | -93,000Source | -26,119,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 30,235,000Source | 25,112,000Source | 34,518,000Source | 25,691,000Source | 33,736,000Source | 24,066,000Source | 114,196,000Source | 103,463,000Source | 156,314,000Source | 98,024,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -4,545,000Source | -31,504,000Source | 11,293,000Source | -16,711,000Source | 15,054,000Source | -13,311,000Source | -20,169,000Source | -120,475,000Source | -159,549,000Source | -179,427,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 81,626,000Source | 19,000Source | 3,382,000Source | -12,000Source | 38,821,000Source | -264,000Source | 72,359,000Source | 5,830,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -3,083,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -3,000Source | -828,000Source | -17,000Source | -2,057,000Source | -20,000Source | -1,104,000Source | -3,198,000Source | -5,059,000Source | -11,676,000Source | -10,582,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 2Source | -3.08Source | -0.01Source | -1Source | 1.03Source | -1.03Source | 0Source | -10.59Source | -0.69Source | -0.78Source |
| Earnings Per Share, DilutedUSD per share | — | — | 1.94Source | -3.08Source | -0.01Source | -1Source | 1.02Source | -1.03Source | 0Source | -10.59Source | -0.69Source | -0.78Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 31,886,000Source | 21,550,000Source | 41,338,000Source | 28,117,000Source | 37,941,000Source | 24,469,000Source | 29,734,000Source | 21,473,000Source | 357,889Source | 281,743Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 32,858,000Source | 21,550,000Source | 41,338,000Source | 28,117,000Source | 38,285,000Source | 24,469,000Source | 29,734,000Source | 21,473,000Source | 357,889Source | 281,743Source |
| Interest Expense (non-operating)USD | — | — | 13,244,000Source | 36,748,000Source | 15,363,000Source | 13,343,000Source | 14,690,000Source | 12,983,000Source | 55,618,000Source | 120,421,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 300,000Source | 500,000Source | 1,500,000Source | 2,200,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 583,000Source | 3,203,000Source | 9,999,000Source | 13,343,000Source | 13,588,000Source | 6,946,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -200,000Source | -29,000Source | -100,000Source | -400,000Source |
| General and Administrative ExpenseUSD | — | — | 10,860,000Source | 17,275,000Source | 8,466,000Source | 15,518,000Source | 6,860,000Source | 15,718,000Source | 54,392,000Source | 71,878,000Source | 78,739,000Source | 81,007,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 602,000Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 6,620,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | 2,526,000Source | 0Source | -1,350,000Source | 0Source | -26,345,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -13,170,000Source | -35,729,000Source | -15,242,000Source | -13,289,000Source | -14,669,000Source | -12,795,000Source | -55,273,000Source | -117,626,000Source | -97,925,000Source | -61,863,000Source |
| Investment Income, InterestUSD | — | — | 74,000Source | 1,019,000Source | 121,000Source | 54,000Source | 21,000Source | 188,000Source | 345,000Source | 2,795,000Source | — | — |
| Labor and Related ExpenseUSD | — | — | 9,294,000Source | 15,283,000Source | 4,136,000Source | 11,327,000Source | 6,895,000Source | 12,105,000Source | 39,664,000Source | 61,814,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 63,860,000Source | -66,440,000Source | -604,000Source | -28,009,000Source | 39,172,000Source | -25,320,000Source | -101,000Source | -227,427,000Source | -245,974,000Source | -220,286,000Source |
| Nonoperating Income (Expense)USD | — | — | -19,298,000Source | 19,000Source | 856,000Source | -12,000Source | -208,000Source | -264,000Source | -2,220,000Source | 5,830,000Source | 37,000Source | 12,571,000Source |
| Other Cost and Expense, OperatingUSD | — | — | 5,464,000Source | 6,756,000Source | 3,407,000Source | 8,355,000Source | 945,000Source | 6,250,000Source | 24,488,000Source | 28,441,000Source | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 54,000Source | 54,000Source | 54,000Source | 54,000Source | 54,000Source | 54,000Source | 216,000Source | 215,000Source | 213,000Source | 212,000Source |
| Research and Development ExpenseUSD | — | — | 23,596,000Source | 41,058,000Source | 14,759,000Source | 26,710,000Source | 11,822,000Source | 21,522,000Source | 79,338,000Source | 155,528,000Source | 234,569,000Source | 186,691,000Source |
| Costs and Expenses | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-298893
Registration 333-298111
Registration 333-297556
Filing attachments
agen-ex4_11.htm · 10-Q · 2026-11-05
AMENDMENT TO NOTES, EXTENSION OF WARRANTS AND SALE OF NEW WARRANTS This Amendment to Notes, Extension of Warrants and Sale of New Warrants (this “Amendment”) is entered into this 29th day of June, 2026 by and between (a) Agenus Inc., a Delaware corporation, having an address at 3 Forbes Road, Lexington, MA 02421 (the “Borrower”), and (b) Alice Saraydarian, Khalil Barrage and Nicky V LLC (collectively, the “Remaining Purchasers”). WITNESSETH WHEREAS, the Borrower, the Remaining Purchasers and…
Read attachment ↗agen-ex99_1.htm · 8-K · 2026-11-05
FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engagement advances preparations across the Americas, Europe and Asia • Peer-reviewed NEST and UNICORN manuscripts report approximately 30% pathologic complete responses with short-course BOT+BAL in MSS colon cancer; no obser…
Read attachment ↗agen-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 agen-ex99_1.htm EX-99.1 EX-99.1 FOR IMMEDIATE RELEASE Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer • Previously announced oversubscribed $85 million private placement, with up to $255 million in potential proceeds from milestone-aligned warrants, supports ROBBIN execution • ROBBIN addresses approximately 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more …
Read attachment ↗d111026dex41.htm · 8-K · 2026-07-13
EX-4.1 2 d111026dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUC…
Read attachment ↗d111026dex42.htm · 8-K · 2026-07-13
EX-4.2 3 d111026dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO TH…
Read attachment ↗d111026dex43.htm · 8-K · 2026-07-13
EX-4.3 4 d111026dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO TH…
Read attachment ↗